https://www.selleckchem.com/pr....oducts/Omecamtiv-mec
ces in QA-PFS and Q-TWiST confirm the benefit of rucaparib versus placebo in all predefined cohorts. Doxorubicin is a standard of care in patients with advanced, inoperable soft tissue sarcoma (STS). We tested whether pazopanib has efficacy comparable to that of doxorubicin in elderly patients with STS and offers superior tolerability for hematologic toxicity. Patients age 60 years or older without previous systemic treatment for progressive advanced or metastatic STS who had Eastern Cooperative Oncology Group perf
Like
Comment
Share
